Drug Profile
Licaminlimab - Novartis/Oculis Pharma
Alternative Names: ESBA-1622; LME-636; OCS-02Latest Information Update: 01 Mar 2024
Price :
$50
*
At a glance
- Originator ESBATech
- Developer Alcon; Oculis Pharma
- Class Anti-inflammatories; Eye disorder therapies; Immunoglobulin Fv fragments
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Dry eyes; Uveitis
Most Recent Events
- 28 Feb 2024 Oculis Pharma completes enrolment in the phase IIb RELIEF trial for Dry eyes in USA (Ophthalmic, Drops)
- 29 Nov 2023 Oculis Pharma initiates the RELIEF phase IIb trial for Dry eyes in USA (Ophthalmic, Drops) (NCT05896670)
- 23 Aug 2023 Apexigen has been acquired and merged into Pyxis Oncology